We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0727 | -10.4785240703 | 0.6938 | 0.715 | 0.6115 | 194702 | 0.65351597 | CS |
4 | -0.0899 | -12.6441631505 | 0.711 | 0.74 | 0.6115 | 117652 | 0.68031931 | CS |
12 | -0.0438 | -6.58745676042 | 0.6649 | 0.94 | 0.6 | 198136 | 0.76316811 | CS |
26 | 0.0217 | 3.62028695362 | 0.5994 | 0.94 | 0.5561 | 274547 | 0.69209306 | CS |
52 | -1.7589 | -73.9033613445 | 2.38 | 3.7 | 0.5 | 366216 | 0.95535614 | CS |
156 | -4.2389 | -87.2201646091 | 4.86 | 16.41 | 0.5 | 278784 | 3.07880735 | CS |
260 | -15.1489 | -96.0615091947 | 15.77 | 17.99 | 0.5 | 241629 | 3.25886624 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions